Epinephrine, a minute molecule drug, exerts its action as an adrenergic receptor agonist by targeting the adrenergic receptor, exhibiting an extensive list of active indications.

Orchard Therapeutics has obtained U.S. FDA endorsement for Lenmeldy™, a proprietary treatment branded as atidarsagene autotemcel, designed exclusively for young patients diagnosed with early-stage Metachromatic Leukodystrophy.

Off-label use is prescribing or administering a drug in a way not formally sanctioned by regulatory bodies like the FDA or EMA, such as for unapproved conditions, age groups, or dosages.

The deal encompasses a clinical-phase actinium radioconjugate aimed at PSMA to combat prostate cancer, a collection of radioconjugate products in development, and cutting-edge research, development, and production infrastructure.

Progesterone, a diminutive molecule drug, acts as a modulator of the progesterone receptor (PR), exhibiting a broad spectrum of active indications.

Lynparza and Imfinzi substantially increased the average response time, outperforming chemotherapy, in providing clinical advantages for individuals with advanced or relapsed endometrial cancer that shows proficient DNA mismatch repair.

A "blockbuster drug" is a term used in the pharmaceutical industry to describe a medication that is extremely successful in the market, generating significant sales and revenue.

Intellia Therapeutics has revealed the initiation of their Phase 3 clinical trial named MAGNITUDE, where the first participant received a one-time CRISPR therapy, NTLA-2001, aimed at treating cardiac amyloidosis caused by transthyretin.

Glutathione, a diminutive molecule drug, is a versatile medication used to treat a diverse range of medical conditions.

During the 2024 ACS Spring Meeting, Brenig Therapeutics showcased novel findings related to their leading LRRK2 inhibitor, which is aimed at tackling Parkinson's disease.

In this article, we will focus on Sosei Heptares, a leading company in the field of GPCR new drug development, and its GPCR research and development pipeline.

On March 14, 2024, Eli Lilly unveiled a WO patent for a crystalline salt form of an FGFR3 inhibitor, likely relating to LOXO-435's structure, within the pyrimido[4,5-b]pyrazine compound class.